Please ensure Javascript is enabled for purposes of website accessibility

Why Opko Health Skyrocketed 17.4% in February

By Todd Campbell - Mar 3, 2016 at 7:23PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Anticipating strong fourth-quarter results and a positive decision from the FDA, investors bid up shares in the company last month.

SOURCE: OPKO HEALTH.

What: Ahead of its fourth-quarter earnings release on February 29 and a key FDA approval decision slated for March 29, shares in Opko Health (OPK 3.95%) jumped by 17.4% in February.

So What: Opko Health is run by iconic healthcare entrepreneur Phillip Frost, and during the past few years, Frost has been actively acquiring companies to position Opko Health as a leader in both diagnostics and biopharma. In Q4, Opko Health reports that acquiring the specialty lab services company Bio-Reference Labs resulted in revenue soaring 983%, to $276 million, and EPS improving to $0 from a loss last year.

Opko Health's fourth-quarter results also benefited from a $15 million milestone payment tied to the FDA approval of partner Tesaro's (NASDAQ: TSRO) Varubi, a drug for the treatment of chemotherapy-induced nausea. Varubi launched in November, and while fourth-quarter revenue from it was immaterial, Tesaro believes Varubi represents a $1 billion opportunity.

Opko Health also recognized $17.7 million in revenue from Pfizer (PFE -0.23%) last quarter related to Pfizer's licensing of Opko Health's long-lasting human growth hormone in December 2014.

The company's full-year revenue similarly benefited from the inclusion of Bio-Reference Labs sales and Tesaro- and Pfizer-related revenue. Overall, Opko Health reports sales grew 439.7%, to $491.7 million in 2015, and the company's net loss per share improved 85.4%, to $0.06.

Now what: On March 29, the FDA is scheduled to make a decision on Opko Health's wholly owned vitamin D prohormone Rayaldee, which could potentially offer a more-effective way of increasing vitamin D in chronic kidney-disease patients than current solutions. Opko Health estimates that, if approved, Rayaldee will compete in a market it values at $12 billion.

In addition to potential upside from Rayaldee, Opko Health's revenue and earnings could benefit if Bio-Reference Labs' sales team can spark demand for Opko Health's 4Kscore prostate cancer test. The 4Kscore test has yet to make meaningful inroads, but 200 of Bio-Reference Lab's sales people have been trained to sell it, and the company reports that initial results from their efforts are encouraging.

The approval of the chemo-induced nausea and vomiting drug Varubi last fall could also add revenue this year. Tesaro (NASDAQ: TSRO) launched Varubi in November, and while the market for CINV drugs is competitive, Varubi royalties could eventually be meaningful if Tesaro can establish a foothold in the indication.

Additionally, phase 3 top-line data for Opko Health's human growth hormone is anticipated later in the year, and if results are good, then this drug could pay off handsomely. As part of its licensing deal, Pfizer's agreed to $275 million in regulatory milestones, plus royalties or profit-sharing.

Overall, there are a lot of catalysts that could move the needle for Opko Health this year, so it's not surprising that investors are placing bets. Obviously, plenty can go wrong for the company from here, but investors willing to take on some risk might want to buy shares.

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$52.31 (-0.23%) $0.12
OPKO Health, Inc. Stock Quote
OPKO Health, Inc.
OPK
$2.63 (3.95%) $0.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.